These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37883217)

  • 41. Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism.
    Haze T; Ozawa M; Kawano R; Haruna A; Ohki Y; Suzuki S; Kobayashi Y; Fujiwara A; Saka S; Tamura K; Hirawa N
    Hypertens Res; 2023 May; 46(5):1132-1144. PubMed ID: 36754972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
    Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Green tea could improve elderly hypertension by modulating arterial stiffness, the activity of the renin/angiotensin/aldosterone axis, and the sodium-potassium pumps in old male rats.
    Gao J; Akbari A; Wang T
    J Food Biochem; 2022 Dec; 46(12):e14398. PubMed ID: 36181277
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers.
    Mulatero P; Groessl M; Vogt B; Schumacher C; Steele RE; Brooks A; Hossack S; Brunner HR
    Br J Clin Pharmacol; 2023 Aug; 89(8):2483-2496. PubMed ID: 36914591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?
    Lim PO; Struthers AD; MacDonald TM
    J Hypertens; 2002 Jan; 20(1):11-5. PubMed ID: 11791020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
    Hashimoto A; Takeda Y; Karashima S; Kometani M; Aono D; Demura M; Higashitani T; Konishi S; Yoneda T; Takeda Y
    Hypertens Res; 2020 Oct; 43(10):1099-1104. PubMed ID: 32398797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aldosterone Stimulates Its Biosynthesis Via a Novel GPER-Mediated Mechanism.
    Caroccia B; Seccia TM; Piazza M; Prisco S; Zanin S; Iacobone M; Lenzini L; Pallafacchina G; Domening O; Poglitsch M; Rizzuto R; Rossi GP
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6316-6324. PubMed ID: 31125081
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
    Shimosawa T
    Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dietary salt modifies the blood pressure response to renin-angiotensin inhibition in experimental chronic kidney disease.
    Bovée DM; Uijl E; Severs D; Rubio-Beltrán E; van Veghel R; Maassen van den Brink A; Joles JA; Zietse R; Cuevas CA; Danser AHJ; Hoorn EJ
    Am J Physiol Renal Physiol; 2021 Apr; 320(4):F654-F668. PubMed ID: 33586496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical potential of renin inhibitors and angiotensin antagonists.
    Cody RJ
    Drugs; 1994 Apr; 47(4):586-98. PubMed ID: 7516858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof.
    Veldhuizen GP; Alnazer RM; de Leeuw PW; Kroon AA
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):283-289. PubMed ID: 34515895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.
    Monge M; Lorthioir A; Bobrie G; Azizi M
    J Renin Angiotensin Aldosterone Syst; 2013 Dec; 14(4):285-9. PubMed ID: 24222656
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
    Morimoto S; Ichihara A
    Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity.
    Lim PO; Jung RT; MacDonald TM
    J Hum Hypertens; 2002 Mar; 16(3):153-8. PubMed ID: 11896503
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mineralocorticoid antagonism and cardiac hypertrophy.
    Nagata K
    Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Approach to the Patient on Antihypertensive Therapy: Screen for Primary Aldosteronism.
    Mulatero P; Bertello C; Veglio F; Monticone S
    J Clin Endocrinol Metab; 2022 Nov; 107(11):3175-3181. PubMed ID: 35964152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of antihypertensive drugs in the subtype diagnosis of primary aldosteronism by adrenal venous sampling.
    Nagasawa M; Yamamoto K; Rakugi H; Takeda M; Akasaka H; Umakoshi H; Tsuiki M; Takeda Y; Kurihara I; Itoh H; Ichijo T; Katabami T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Ogo A; Okamura S; Miyauchi S; Yanase T; Suzuki T; Kawamura T; Naruse M;
    J Hypertens; 2019 Jul; 37(7):1493-1499. PubMed ID: 31033727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.